argenx (NASDAQ:ARGX) Earns Outperform Rating from William Blair

argenx (NASDAQ:ARGX)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a research note issued on Friday,RTT News reports.

Other equities analysts have also issued reports about the stock. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target for the company in a research report on Tuesday, November 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $675.00 target price (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. Wedbush reissued an “outperform” rating and set a $655.00 price target on shares of argenx in a report on Tuesday, December 3rd. Evercore ISI upped their price objective on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Piper Sandler lifted their target price on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, argenx currently has an average rating of “Moderate Buy” and a consensus target price of $661.17.

argenx Trading Down 1.0 %

argenx stock traded down $6.08 during trading on Friday, reaching $618.62. The company had a trading volume of 195,907 shares, compared to its average volume of 270,645. The firm has a market capitalization of $37.59 billion, a price-to-earnings ratio of -703.45 and a beta of 0.58. The firm’s 50-day simple moving average is $642.61 and its 200 day simple moving average is $589.72. argenx has a 52 week low of $349.86 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, analysts predict that argenx will post 3.13 earnings per share for the current year.

Institutional Trading of argenx

A number of large investors have recently made changes to their positions in ARGX. GeoWealth Management LLC grew its position in argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after acquiring an additional 18 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in shares of argenx by 5.6% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after purchasing an additional 20 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after purchasing an additional 21 shares during the period. Farther Finance Advisors LLC increased its position in shares of argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after purchasing an additional 21 shares during the last quarter. Finally, Dynasty Wealth Management LLC increased its position in shares of argenx by 3.4% during the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.